key: cord-0821247-md3e3wpn
authors: Varikasuvu, Seshadri Reddy; Dutt, Naveen; Thangappazham, Balachandar; Varshney, Saurabh
title: Diabetes and COVID-19: A pooled analysis related to disease severity and mortality
date: 2020-08-29
journal: Prim Care Diabetes
DOI: 10.1016/j.pcd.2020.08.015
sha: eb1ea7e1844e29b9501a753a3762d5f1ca8cdfe0
doc_id: 821247
cord_uid: md3e3wpn

Globally, COVID-19 has become a major concern for the diabetic community. We conducted a pooled analysis and constructed a forest plot for the association between diabetes and COVID-19 progression in 47 studies. A random effects meta-analysis (Mantel-Haenszel method) was conducted to estimate the outcomes effect size as odds ratios (OR) and 95% confidence intervals (CI) using Review Manager Software version 5.3. COVID-19 patients with diabetes have a significantly higher risk of disease severity (OR = 2.20, 95% CI = 1.69 – 2.86, p < 0.00001) and associated mortality outcomes (OR = 2.52, 95% CI = 1.93 – 3.30, p = < 0.00001).

Ever since the outbreak of coronavirus disease 2019 (COVID- 19) due to a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of infected cases and associated mortalities due to COVID-19 are growing. Studies have linked fatal outcomes in COVID-19 to the associated comorbidities. Evidence reported in the Journal of Diabetes and Centers for Disease Control and Prevention (CDC) showed diabetes as the most important comorbidity associated with a 50% higher risk of fatal outcomes in COVID-19 cases with diabetes than their non-diabetic counterparts [1] [2] [3] . Considering the global concern for COVID-19 pandemic in the diabetes community, we aim to evaluate the risk of disease severity and mortality in association with diabetes in COVID-19 patients.

This meta-analysis was planned as a part of our PROSPERO registered protocol (CRD42020186661), and relevant studies were identified through searching PubMed, Cochrane, medRxiv and other databases. Studies reporting diabetic proportions in subgroups of COVID-19 patients (Severe Vs. Non-severe & Mortal Vs. Survival) were included. Other study types and reports with no data on diabetic numbers were excluded.

The proportions of COVID-19 patients with diabetes in severe/mortal & non-severe/survival groups were used to estimate the risk of disease progression associated with diabetes. Further, a separate outcome analysis was conducted to study the relationship of diabetes with disease severity (Severe vs. Non-severe) and mortality (Survival vs. Non-survival) in COVID-19

A random effects meta-analysis (Mantel-Haenszel method) was conducted to estimate the outcomes effect size as odds ratios (OR) and 95% confidence intervals (CI) using Review Manager Software version 5.3. The stability and publication bias were tested by a one-study leave-out sensitivity analysis and funnel plot asymmetry, respectively. Heterogeneity was assessed using the I 2 statistic. A p-value of <0.05 was considered to be statistically significant. More information on literature search and results are presented in the Supplementary Material.

In this meta-analysis, a total of 47 relevant studies were included for the pooled outcome analysis . All the studies confirmed diagnosis using the real-time reverse transcription polymerase chain reaction test. Overall, the diabetic proportions were 1009/3773 and J o u r n a l P r e -p r o o f 1360/9495 in severe/mortal and non-severe/survival groups of COVID-19 cases, respectively.

The pooled outcome for the risk of disease progression indicated a significant impact of diabetes in COVID-19 cases (OR = 2.32, 95% CI = 1.90 -2.83, Z = 8.30, p<0.00001, I 2 = 55%, p<0.0001) (Fig. 1 ). The symmetrical funnel plot shown in Fig. 2 suggests no publication bias and sensitivity analysis indicated that the stability of overall result is not influenced by leaving-out any particular study. More information on search results, study characteristics and quality assessment are presented in the Supplementary Table 1 .

The diabetic proportions were 750/2894 and 931/6203 in severe and non-severe groups of COVID-19 cases, respectively. And, the respective diabetic proportions were 259/879 and 429/3292 in mortal and survival groups of COVID-19. As shown in Fig. 1 , the subgroup analysis showed that diabetes related significantly with COVID-19 disease severity (OR = 2.20, 95% CI = 1.69 -2.86, Z = 5.82, p<0.00001, I 2 = 58%, p<0.0001) and mortality (OR = 2.52, 95% CI = 1.93 -3.30, Z = 6.79, p<0.00001, I 2 = 31%, p = 0.08) as well. Though no significant heterogeneity was observed for the association of diabetes with mortality outcomes, the overall results should be viewed with caution to the heterogenous coexisting comorbidities across the included studies.

Our results clearly indicate risk of disease progression and mortality is significantly high in COVID-19 patients with diabetes than in those without diabetes. It has been reported that individuals with impaired glucose tolerance or diabetes to have 50-60% higher risk of pulmonary infection [2, 3] . Recent evidence suggests an increased risk of severe Adult Respiratory Distress Syndrome and multi-organ failure complications in diabetic patients.

Globally, during the COVID-19 pandemic, diabetic cases consists of up to 50% COVID-19 cases [3] .

As an important comorbid metabolic disorder, diabetes characterised by hyperglycemia has been reported to downregulate immune response and increased inflammation. It has also been proposed that coronavirus through angiotensin-converting enzyme 2 (ACE2) receptors may result in cell damage and disease progression [2, 3] . The available evidence shows that the 

Beyond the virus: Ensuring continuity of care for people with diabetes during COVID-19

Care for diabetes with COVID 19: Advice from China

Practical recommendations for the management of diabetes in patients with COVID-19

ICU and Ventilator Mortality Among Critically Ill Adults With Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

The role of interleukin 6 in monitoring severe case of coronavirus disease 2019

Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome

A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention

Clinical characteristics and co-infections of 354 hospitalized patients with

Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease

Clinical characteristics of refractory COVID-19 pneumonia in n

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Low testosterone levels predict clinical adverse outcomes in SARS CoV 2 pneumonia patients

The value of clinical parameters in predicting the severity of COVID 19

Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan

Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients

Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Early risk factors of the exacerbation of Coronavirus disease 2019 pneumonia

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical Features of 69 Cases with Coronavirus Disease

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019

Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single center, Retrospective, Observational Study in Wuhan

Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

COVID 19 in elderly kidney transplant recipients

Diabetes is a risk factor for the progression and prognosis of COVID-19

Prognostic value of C-reactive protein in patients with COVID-19 n

Clinical Characteristics of Critically Ill Patients Co-infected with SARS-CoV-2 and the Influenza Virus in Wuhan, China

Clinical and Laboratory Predictors of In-Hospital Mortality in 305 Patients with COVID-19: A Cohort Study in Wuhan

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in

China: a single-centered, retrospective, observational study

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan